Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms

European Neuropsychopharmacology

Volumn 16, Issue SUPPL. 3, 2006, Pages

  Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atypical antipsychotic; Psychotic symptoms; Schizophrenia; Treatment optimisation

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANXIETY DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DELUSION; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HOSTILITY; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SEDATION; SELF ESTEEM; SIDE EFFECT; SOCIAL ASPECT; TARDIVE DYSKINESIA; VOCATION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HALLUCINATIONS; HUMANS; LONG-TERM CARE; NEUROPSYCHOLOGICAL TESTS; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33746809863     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.06.004     Document Type: Review

References (37)

1. Conley R.R., and Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 158 (2001) 765-774
2. Cornblatt B., Kern R.S., Carson W.H., Ali M.W., Luo X., and Green M. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int. J. Neuropsychopharmacol. 5 (2002) S185
3. Corrigan P.W., Liberman R.P., and Engel J.D. From noncompliance to collaboration in the treatment of schizophrenia. Hosp. Commun. Psychiatry 41 (1990) 1203-1211
4. Crow T.J., MacMillan J.F., Johnson A.L., and Johnstone E.C. A randomised controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry 148 (1986) 120-127
5. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
6. Glick I.D., and Marder S.R. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 66 (2005) 638-641
7. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 (1996) 321-330
8. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 (2000) 119-136
9. Hofer A., Kemmler G., Eder U., Edlinger M., Hummer M., and Fleischhacker W.W. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J. Clin. Psychiatry 65 (2004) 932-939
10. Hogarty G.E., Goldberg S.C., Schooler N.R., and Ulrich R.F. Drug and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates. Arch. Gen. Psychiatry 31 (1974) 603-608
11. Horan W.P., and Blanchard J.J. Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. Schizophr. Res. 65 (2003) 125-137
12. Kane J.M. Schizophrenia. N. Engl. J. Med. 334 (1996) 34-41
13. Kasper S., and Winkler D. Addressing the limitations of the CATIE study. World J. Biol. Psychiatry 7 (2006) 126-127
14. Kasper S., Lerman M.N., McQuade R.D., Saha A., Carson W.H., Ali M., Archibald D., Ingenito G., Marcus R., and Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6 (2003) 325-337
15. Kerwin R.W. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br. J. Psychiatry 164 (1994) 141-148
16. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
17. Markou P. Depression in schizophrenia: a descriptive study. Aust. N. Z. J. Psychiatry 30 (1996) 354-357
18. McCreadie R.G. Managing the first episode of schizophrenia: the role of new therapies. Eur. Neuropsychopharmacol. 6 (1996) S3-S5
19. McQuade R.D., Jody D., Kujawa M., Carson W., and Iwamoto T. Long-term weight effects of aripiprazole vs olanzapine. Abstract Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA (2003). http://www.psych.org/public_info/libr_publ/abstracts.cfm Available from http://www.psych.org/public_info/libr_publ/abstracts.cfm accessed 12 May 2006
20. Meagher D.J., Quinn J.F., Bourke S., Linehan S., Murphy P., Kinsella A., Mullaney J., and Waddington J.L. Longitudinal assessment of psychopathological domains over late-stage schizophrenia in relation to duration of initially untreated psychosis: 3-year prospective study in a long-term inpatient population. Psychiatry Res. 126 (2004) 217-227
21. Palmer B.W., Heaton R.K., Paulsen J.S., Kuck J., Braff D., Harris M.J., Zisook S., and Jeste D.V. Is it possible to be schizophrenic yet neuropsychologically normal?. Neuropsychology 11 (1997) 437-446
22. Peuskens J., Van Baelen B., De Smedt C., and Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia. Int. Clin. Psychopharmacol. 15 (2000) 343-349
23. Pigott T.A., Carson W.H., Saha A.R., Torbeyns A.F., Stock E.G., and Ingenito G.G. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry 64 (2003) 1048-1056
24. Rosenheck R., Perlick D., Bingham S., Liu-Mares W., Collins J., Warren S., Leslie D., Allan E., Campbell E.C., Caroff S., Corwin J., Davis L., Douyon R., Dunn L., Evans D., Frecska E., Grabowski J., Graeber D., Herz L., Kwon K., Lawson W., Mena F., Sheikh J., Smelson D., and Smith-Gamble V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290 (2003) 2693-2702
25. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr. Clin. North Am. 9 (1986) 193-206
26. Roy A., Thompson R., and Kennedy S. Depression in chronic schizophrenia. Br. J. Psychiatry 142 (1983) 465-470
27. Schooler N.R. Maintaining symptom control: review of ziprasidone long-term efficacy data. J. Clin. Psychiatry 64 (2003) 26-32
28. Schooler N.R., Keith S.J., Severe J.B., Matthews S.M., Bellack A.S., Glick I.D., Hargreaves W.A., Kane J.M., Ninan P.T., Frances A., Jacobs M., Lieberman J.A., Mance R., Simpson G.M., and Woerner M.G. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch. Gen. Psychiatry 54 (1997) 453-463
29. Simpson G.M., Weiden P., Pigott T., Murray S., Siu C.O., and Romano S.J. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am. J. Psychiatry 162 (2005) 1535-1538
30. Stock E.G., Archibald D.G., Tourkodimitris S., Kujawa M.J., Marcus R., and Carson W.H. Long-term effects of aripiprazole on affective symptoms of schizophrenia. Abstract Presented at the 156th Annual Meeting of the American Psychiatric Association, San Francisco, CA (2003). http://www.psych.org/public_info/libr_publ/abstracts.cfm Available from http://www.psych.org/public_info/libr_publ/abstracts.cfm accessed 12 May 2006
31. Tollefson G.D., Sanger T.M., Lu Y., and Thieme M.E. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry 55 (1998) 250-258
32. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley Jr. C., and Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17 (1997) 407-418
33. Velligan D.I., Bow-Thomas C.C., Mahurin R.K., Miller A.L., and Halgunseth L.C. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. J. Nerv. Ment. Dis. 188 (2000) 518-524
34. Weiden P., and Glazer W. Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr. Q. 68 (1997) 377-392
35. Weiden P.J., and Miller A.L. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J. Psychiatr. Pract. 7 (2001) 41-47
36. Weinberger D.R., and Gallhofer B. Cognitive function in schizophrenia. Int. Clin. Psychopharmacol. 12 (1997) S29-S36
37. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472